Petra Vidláková
Masaryk University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Petra Vidláková.
Vaccine | 2003
Tomáš Büchler; Roman Hájek; Lida Bourkova; Lucie Kovarova; Romana Musilová; Alena Buliková; M. Doubek; Adam Svobodník; Iveta Mareschová; Pavlina Vanova; Eva Tuzova; Petra Vidláková; Vorlícek J; Miroslav Penka
Dendritic cells (DCs) are antigen-presenting cells that play a critical role in the induction of cytotoxic T-lymphocytes. An optimal method for the generation of DC for clinical use remains to be established. The aim of our study was to find an optimal cytokine combination for DC generation from peripheral blood stem cells (PBSC) and peripheral blood mononuclear cells (PBMC) in serum-free conditions. Serial immunophenotyping enabled us to observe changes in DC content during the culture as well as the development of maturation and activation markers. As a source for DC culture, we used PBSC from patients with multiple myeloma after stem cell mobilization using cyclophosphamide and G-CSF, or PBMC from healthy donors without mobilization. The cells were cultured in a serum-free medium with different cytokine combinations including GM-CSF, TNF-alpha, Flt-3, CD40L, IFN-gamma, IL-1alpha, IL-6, PGE1, and IL-4. The cell cultures were evaluated by immunophenotyping. For PBMC, interleukin-12 assay was performed. For PBSC, the yield of DC as determined by CD83+ cell count ranged from 0. 6 x 10(5) to 30.1 x 10(4) (mean: 9.4 x 10(4)) of DC generated per 1 x 10(6) of initially plated nucleated cells from apheresis. This yield corresponded to (0.3-19.1) x 10(5) (mean: 4.3 x 10(5)) per 1 x 10(6) of CD34+ cells in the apheresis products. For PBMC, the yield was (0.4-24.8) x 10(4) (mean: 2.4 x 10(4)) of DC generated per 1 x 10(6) of initially plated mononuclear cells from venous blood. The cultured cells expressed the mature immunophenotype. No significant differences in cell yield or immunophenotype were detected when comparing different cytokine combinations.
Clinical Immunology | 2007
Eva Matejkova; Zuzana Hroteková; Drahomíra Kyjovská; Jaroslav Michálek; Petra Vidláková
BACKGROUND Graft-versus-host disease (GVHD) is a severe complication of allogeneic transplantation of hematopoietic stem cells. Donor T cells play a major role in GVHD leading to the host tissue damage, mainly the skin, liver, and gastrointestinal tract. A selective depletion using an anti-CD25 immunotoxin can eliminate harmful alloreactive T cells while preserving other donor T cells with antileukemic and antiinfectious reactivity. PATIENTS AND METHODS We performed 15 mixed lymphocyte reactions with clinical specimens from 12 patients with various types of leukemia (7x AML, 3x ALL, 1x CML, 1x CLL) and PBMC from 15 healthy volunteers from Transfusive station FN Brno Bohunice. RESULTS In our experiments we have demonstrated, that antileukemic (GVL) effect of donor, especially CD4+ T cells was well preserved (7.46%), while unfavourable alloreactive (GVH) reaction of donor T cells was completely removed. The graft-versus-host (GVH) reactivation of donor cells was negligible ever after repeated stimulation with irradiated patients PBMC. CONCLUSION We have shown that anti-CD25 immunotoxin (IT), RFT5-SMPT-dgA, launched against alpha chain for human interleukin 2 (IL-2), led to long-term selective depletion of alloreactive donor T cell clones while their antileukemic activity was well preserved. Base on our results the clinical phase I/II study was designed. This study was initiated in year 2007 in three clinical centers in Czech Republic.
Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti | 2009
Darina Očadlíková; Lenka Zahradová; Lucie Kovarova; Jana Smejkalová; Luděk Pour; Petra Vidláková; Drahomíra Kyjovská; Jana Moravcová; Marcela Rycová; H. Novotná; Jelínková I; Miroslav Penka; Jaroslav Michálek; Hájek R
Klinická onkologie Supplement 2008 | 2008
Ivana Burešová; Jana Čumová; Lucie Kovářová; Drahomíra Kyjovská; Petra Vidláková; Renata Suská; Tomáš Perutka; Jana Moravcová; Marcela Rycová; Miroslav Penka; Roman Hájek
Klinická onkologie Supplement 2008 | 2008
Jana Čumová; Ivana Burešová; Lucie Kovářová; Drahomíra Kyjovská; Petra Vidláková; Renata Suská; Tomáš Perutka; Jana Moravcová; Marcela Rycová; Miroslav Penka; Roman Hájek
Neoplasma | 2003
Tomáš Büchler; Hájek R; Lucie Kovarova; Romana Musilová; Ludmila Bourková; Zdeněk Čech; Vánová P; Eva Tůzová; Petra Vidláková; Jiří Vorlíček; Miroslav Penka
Archive | 2012
Drahomíra Kyjovská; Petra Vidláková; Martina Almáši; Lucie Říhová; Fedor Kryukov; Jana Smejkalová; Miroslav Penka; Roman Hájek
Archive | 2011
Jana Mužíková; Jana Smejkalová; Dana Hrušková; Helena Poláková; Drahomíra Kyjovská; Petra Vidláková; Klára Mollová; Kateřina Vopěnková; Veronika Foltánková; Roman Hájek
Archive | 2011
Petra Vidláková; Klára Mollová; Lenka Zahradová; Darina Očadlíková; Drahomíra Kyjovská; Roman Hájek
Archive | 2010
Petra Vidláková; Lucie Kordačová; Marek Cibulka; Jana Smejkalová; Jaroslav Michálek